Starting mid-2026, Medicare will cover injectable weight-loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound for eligible individuals with severe obesity or related health conditions, at a cost of $245 per month to Medicare and a maximum $50 monthly copay for recipients
Patients considering GLP-1 medications should consult their healthcare provider to discuss whether pharmaceutical intervention is appropriate for their specific clinical situation, including consideration of cardiovascular risk factors, degree of hyperglycemia, and previous response to lifestyle interventions
Any mention of side effects, outcomes, or treatment experiences does not guarantee similar results
Vital signs NAD
Available both as an injection and an oral pill, semaglutide mimics the natural hormone GLP-1, which helps reduce appetite and promotes lasting weight loss